Nicholas Investment Partners LP Makes New $3.87 Million Investment in United Therapeutics Corporation $UTHR

Nicholas Investment Partners LP bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,141 shares of the biotechnology company’s stock, valued at approximately $3,869,000.

Several other large investors also recently made changes to their positions in UTHR. Torren Management LLC bought a new stake in United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics during the 2nd quarter worth $30,000. WealthCollab LLC grew its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. grew its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.0%

United Therapeutics stock opened at $512.88 on Tuesday. The company has a market capitalization of $22.00 billion, a PE ratio of 18.35, a PEG ratio of 1.74 and a beta of 0.59. The firm’s fifty day moving average is $532.35 and its 200 day moving average is $538.04. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the company earned $6.41 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on UTHR shares. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on United Therapeutics in a report on Thursday, August 6th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 434,075 shares of company stock valued at $233,942,595 in the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.